Patents by Inventor G. Sarngadharan
G. Sarngadharan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7232654Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: September 19, 1994Date of Patent: June 19, 2007Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jean-Claude Chermann, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7217508Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: February 22, 1988Date of Patent: May 15, 2007Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Simon Wain-Hobson, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7205102Abstract: This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: June 7, 1995Date of Patent: April 17, 2007Assignees: Institut Pasteur, The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Jean-Claude Chermann, Francoise Barre-Sinoussi, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 6627395Abstract: The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.Type: GrantFiled: June 6, 1995Date of Patent: September 30, 2003Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 6600023Abstract: Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.Type: GrantFiled: February 18, 1993Date of Patent: July 29, 2003Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Publication number: 20030113780Abstract: The present invention is directed to the discovery of antibodies that will react to proteins or nucleic acids bound to particular crosslinkers, but not to the free crosslinkers or free proteins or nucleic acids. Monoclonal antibodies with such binding specificity have widespread applications in receptor-ligand binding, immunodiagnostic and nucleic acid diagnostics.Type: ApplicationFiled: November 4, 2002Publication date: June 19, 2003Inventors: Mangalasseril G. Sarngadharan, Ranajit Pal, Anthony L. DeVico
-
Publication number: 20030039663Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanavalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.Type: ApplicationFiled: July 17, 2001Publication date: February 27, 2003Inventors: Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
-
Patent number: 6503736Abstract: The present invention is directed to the discovery of antibodies that will react to proteins or nucleic acids bound to particular crosslinkers, but not to the free crosslinkers or free proteins or nucleic acids. Monoclonal antibodies with such binding specificity have widespread applications in receptor-ligand binding, immunodiagnostic and nucleic acid diagnostics.Type: GrantFiled: November 12, 1999Date of Patent: January 7, 2003Assignee: bioMérieux, Inc.Inventors: Mangalasseril G. Sarngadharan, Ranajit Pal, Anthony L. DeVico
-
Patent number: 6465172Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanavalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.Type: GrantFiled: July 17, 2001Date of Patent: October 15, 2002Assignee: bioMérieux, Inc.Inventors: Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
-
Patent number: 6428952Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.Type: GrantFiled: April 19, 1995Date of Patent: August 6, 2002Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, G. Sarngadharan
-
Patent number: 6328973Abstract: The present invention is directed to a method of raising neutralizing antibodies against HIV using a complex of gp120 covalently bonded to CD4 or a complex of gp120 covalently bonded to succinyl concanavalin A.Type: GrantFiled: January 7, 2000Date of Patent: December 11, 2001Inventors: Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
-
Patent number: 6030772Abstract: Neutralizing antibodies against HIV infection are provided. The antibodies are reactive with cryptic epitopes on gp120 and/or CD4 induced by the formation of immunogenic complexes comprising gp120 covalently bonded to CD4 or to succinyl concanvalin A.Type: GrantFiled: May 11, 1998Date of Patent: February 29, 2000Assignee: Akzo Nobel N.V.Inventors: Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
-
Patent number: 5876732Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmuno-precipitation of metabolically labeled gp160 from the same cell line.Type: GrantFiled: April 14, 1998Date of Patent: March 2, 1999Assignee: Akzo Nobel, N.V.Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman, Irene LaRue-Kalisz
-
Patent number: 5843454Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanvalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.Type: GrantFiled: December 20, 1995Date of Patent: December 1, 1998Assignee: Akzo Nobel N.V.Inventors: Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
-
Patent number: 5766844Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmuno-precipitation of metabolically labeled gp160 from the same cell line.Type: GrantFiled: July 3, 1996Date of Patent: June 16, 1998Assignee: Akzo Nobel N.V.Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman, Irene LaRue-Kalisz
-
Patent number: 5736317Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmunoprecipitation of metabolically labeled gp160 from the same cell line.Type: GrantFiled: March 7, 1995Date of Patent: April 7, 1998Assignee: Akzo Nobel N.V.Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman, Irene LaRue-Kalisz
-
Patent number: 5518723Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 bonded covalently to CD4 or to succinyl concanavalin A.Type: GrantFiled: May 8, 1995Date of Patent: May 21, 1996Assignee: Akzo Nobel N.V.Inventors: Anthony L. DeVico, Ranajit Pal, Mangalasseril G. Sarngadharan
-
Patent number: 5135864Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.Type: GrantFiled: November 5, 1987Date of Patent: August 4, 1992Assignees: Institut Pasteur, The United States of America as represented by the Secretary of The Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 5122468Abstract: Human Immunodeficiency Virus (HIV) glycoprotein gp160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III.sub.451, known as 6D5.sub.451, and grown in serum-free medium. gp160 is also produced in its native form using a clone of 6D5.sub.451 that contains no HTLV-III virus.Type: GrantFiled: December 14, 1989Date of Patent: June 16, 1992Assignee: Akzo N.V.Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman
-
Patent number: 5116740Abstract: Human Immunodeficiency Virus (HIV) glycoprotein gp160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III.sub.451, and grown in serum-free medium.Type: GrantFiled: June 7, 1989Date of Patent: May 26, 1992Assignee: Akzo N.V.Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman